Home ›
Leukemia Trials ›
NCT05805098
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.
Trial Details
NCT ID NCT05805098
Phase PHASE2 / PHASE3
Sponsor The First Affiliated Hospital of Soochow University
Status RECRUITING
Cancer Type Leukemia
Interventions Venetoclax Homoharringtonine Cytarabine
Locations (sample) Suzhou, Jiangsu, China|31.30408,120.59538
Key Eligibility Criteria
Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent. patients must have confirmation of AML by WHO criteria, previously untreated, and eligible for treatment with intensive chemotherapy as defined by … Patients \> 18 to ≤ 60 years Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →